Top View
- 205494Orig1s000
- Cell Models of Lipid-Rich Α-Synuclein Aggregation Validate Known Modifiers of Α-Synuclein Biology and Identify Stearoyl-Coa Desaturase
- FDA Orphan Drug Designations for Lysosomal Storage Disorders – A
- The Empire Plan Prescription Drug Program Specialty Pharmacy Program Drug List for Advanced Flexible Formulary
- For Peer Review Only - Page 1 of 59 BMJ Open
- Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
- Supplement 3 List of Treatable Iems
- Self-Administered Specialty Drug List
- Eliglustat (Cerdelga®) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO135
- 5.01.576 Drugs for Rare Diseases
- TITLE: Eliglustat Tartrate, Miglustat, Imiglucerase, Velaglucerase Or A
- Evaluation of Carcinogenicity Studies of Medicinal Products for Human Use Authorised Via the European Centralised Procedure
- Presentation
- Specialty Pharmacy Program Drug List
- 5 Treatment: Present Status and New Trends
- MIGLUSTAT DIPHARMA IS NOW AVAILABLE in SWITZERLAND Chiasso, Switzerland, February 16Th 2021 – – Swiss-Based Dipharma S.A
- State and Specialty Pharmacy Drug Reimbursement Rates
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Repurposing of Miglustat to Inhibit the Coronavirus Severe Acquired
- Past Vs. Present New Generation of Specialty Management
- State and Specialty Pharmacy Drug Reimbursement Rates
- Appendix a - Product Name Index
- Prescribing Information
- Lysosomes As a Therapeutic Target
- Specialty Rx Drug List 2021
- Gaucher Disease – Substrate Reduction Therapy - Cerdelga™ (Eliglustat Capsules), Zavesca® (Miglustat Capsules)
- Select Prior Authorization
- Assessing the Benefit-Risk for New Drugs
- Inherited Metabolic Disorders Presenting with Ataxia
- Inventory of Union and Member State Incentives to Support Research Into, and the Development and Availability Of, Orphan Medicinal Products
- Prior Authorization — Core and Select
- AHFS Pharmacologic-Therapeutic Classification System
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Prior Authorization — Premium
- Gaucher Disease Agents
- A Corporate View of Rare Drugs and the Story of Miglustat – a Perspective
- Current Strategies for the Treatment of Inborn Errors of Metabolism
- Zavesca, INN- Miglustat
- Utah Medicaid Dur Report December 2017 Overview Of
- Prime Therapeutics Specialty Drug Management List
- Metabolomic Studies of Lipid Storage Disorders, with Special Reference to Niemann-Pick Type C Disease: a Critical Review with Future Perspectives
- Evaluation of Miglustat As Maintenance Therapy After
- Methods in Literature-Based Drug Discovery
- Dipharma Announces Successful Development of a Stable, Fast Dissolving Tablet Formulation of Carglumic Acid
- (ADLL) in a Mouse Model of Sandhoff Disease
- Resolution Ap (2000) 1
- Specialty Pharmacy Program Drug List
- Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
- Apple Health "Medicaid" Preferred Drug List Effective January 1, 2020 the Apple Health Preferred Drug List (PDL) Has Products Listed in Groups by Drug Class
- Assessment Report